IRF4 and Miyoshi myopathy: Importantly, MEIS2 has been described by our group as a regulator of proliferation, cell death, and activity of IMiDs in MM, given its ability to regulate the expression of IRF4 and IKZF3, and to act as an endogenous competitor for CRL4CRBN [47].